{
    "id": "wrong_mix_property_leader_00127_2",
    "rank": 8,
    "data": {
        "url": "https://link.springer.com/chapter/10.1007/978-3-030-93997-7_84",
        "read_more_link": "",
        "language": "en",
        "title": "Retinopathy of Prematurity",
        "top_image": "https://static-content.springer.com/cover/book/978-3-030-93997-7.jpg",
        "meta_img": "https://static-content.springer.com/cover/book/978-3-030-93997-7.jpg",
        "images": [
            "https://link.springer.com/oscar-static/images/darwin/header/img/logo-springerlink-39ee2a28d8.svg",
            "https://media.springernature.com/w72/springer-static/cover-hires/book/978-3-030-93997-7?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-030-83434-0?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-3-319-52190-9?as=webp",
            "https://media.springernature.com/w92h120/springer-static/cover-hires/book/978-981-19-1364-8?as=webp",
            "https://link.springer.com/oscar-static/images/logo-springernature-white-19dd4ba190.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Alistair Fielder"
        ],
        "publish_date": "2022-07-25T00:00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/oscar-static/img/favicons/darwin/apple-touch-icon-92e819bf8a.png",
        "meta_site_name": "SpringerLink",
        "canonical_link": "https://link.springer.com/chapter/10.1007/978-3-030-93997-7_84",
        "text": "Au SCL, Tang S-M, Rang S-S, Chen L-J, et al. Association between hyperglycaemia and retinopathy of prematurity: a systematic review and meta-analysis. Sci Rep Sci Rep. 2015;5:9091.\n\nBinenbaum G, Tomlinson LA, de Alba Compomanes AG, et al. Validation of the postnatal growth and retinopathy of prematurity screening criteria. JAMA Ophthalmol. 2020;138:31–7.\n\nBlencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74:35–49.\n\nBOOST II Australia and United Kingdom Collaborative Groups. Outcomes of two trials of oxygen saturation targets in preterm infants. NEJM. 2016;2016(374):749–60.\n\nChiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RV, for the International Committee for the Classification of Retinopathy of Prematurity. An International Committee for the Classification of retinopathy of prematurity, 3rd edition. Ophthalmology. 2021a;128(10):e51–68.\n\nDarlow BA, Husain S. Primary prevention of ROP and the oxygen saturation targeting trials. Semin Perinatol. 2019;43:333–40.\n\nEarly Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol. 2003;121:1684–96.\n\nFierson WM, the American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142:e20183061.\n\nHiggins RD. Oxygen saturation and retinopathy of prematurity. Clin Perinatol. 2019;46:593–9.\n\nHolmström G, Hellström A, Jakobsson P, Lundgren P, et al. Evaluation of new guidelines for ROP screening in Sweden using SWEDROP – a national quality register. Acta Ophthalmol. 2015;93:265–8.\n\nMarlow N, Stahl A, Lepore D, Fielder A, et al. on behalf of the RAINBOW Investigator Group. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): outcomes at two years of a randomised trial. Lancet Child Adolesc Health. 2021;5(10):698–707.\n\nMintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.\n\nQuinn GE, Ying G-S, Daniel E, Hildebrand PL. on behalf of the e-ROP Cooperative Group. Validity of a telemedicine system for the early evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol. 2014;132:1178–84.\n\nReynolds JD, Dobson V, Quinn GE, Fielder AR, et al. on behalf of the CRYO-ROP and LIGHT-ROP Cooperative Groups. Evidence-based screening for retinopathy of prematurity: natural history data from CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol. 2002;120:1470–6.\n\nStahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394:1551–9.\n\nWallace DK, Kraker RT, Freedman SF, et al. Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. 2020;138:698–701.\n\nWilkinson AR, Haines L, Head K, Fielder AR. UK retinopathy of prematurity guideline. Early Hum Dev. 2008;84:71–4."
    }
}